Clene Conference: CEO Says FDA Minutes Suggest CNM-Au8 Data Could Support ALS NDA Filing

Key Points

• FDA minutes said Clene’s proposed CNM‑Au8 data "may be capable of supporting the submission and review of an NDA," though the agency must still review the full data package and Clene is pursuing an accelerated‑approval strategy using a surrogate endpoint rather than survival.
• Clene reports CNM‑Au8 produced roughly a 10% reduction in neurofilament light (NfL) in the HEALEY ALS trial with two additional ~9–11% reductions (including an NIH EAP), and has submitted multiple analyses linking NfL changes to clinical outcomes (survival, ALSFRS‑R, biomarker‑clinical concordance).
• After positive data, Clene raised new capital and expects an additional nearly <$strong>7 million tied to a PDUFA timeline, providing runway to prepare for potential approval next year, while its MS program will require a Phase 3 trial focused on cognition with no early‑approval pathway.

Clene NASDAQ: CLNN President and CEO Rob Etherington said the company recently received FDA minutes from a post-meeting discussion that he described as the fifth meeting with the agency in the past year and a half focused on Clene’s clinical data for CNM-Au8.

Etherington characterized the update as a “monumental week” for the late-stage biopharmaceutical company, noting that in the meeting and minutes “the FDA has stated that the proposed data may be capable of supporting the submission and review of an NDA.” He added that “there’s still a lot of work to do,” and emphasized that the agency will need to review Clene’s full data package and supporting literature before determining whether it agrees with the company’s conclusions.

FDA discussions center on accelerated approval pathway

Etherington said Clene’s interactions with the FDA have evolved following the company’s results in the HEALEY ALS platform trial. He noted that Clene missed the primary endpoint in the HEALEY study and that, while the company believes it has “extraordinary survival data,” survival is not considered a surrogate endpoint for an accelerated approval pathway.

“Survival is strong data,” Etherington said, but he added that it does not qualify as a surrogate endpoint “in the way that the statute is given to FDA.” He said survival can support approval when it is tied to meeting a primary endpoint, but stressed that “the reason to approve the drug is on a neurofilament path” for Clene’s current approach.

Neurofilament light presented as surrogate endpoint

Etherington said Clene is relying on neurofilament light (NfL) as the surrogate endpoint for its intended regulatory strategy in amyotrophic lateral sclerosis (ALS). He stated that CNM-Au8 achieved “a rough 10% improvement in neurofilament light” in HEALEY in what he described as the broader, heterogeneous ALS population, which he referenced as approximately 98% of ALS patients. He contrasted this with SOD1 ALS, which he said represents about 1% to 2% of ALS cases and for which another FDA-approved therapy exists.

According to Etherington, the FDA asked the company to find a second source of evidence for the NfL effect. He said Clene reported in December that it had done so, achieving roughly a 9% to 11% reduction in NfL “roughly twice,” with both results statistically significant, including in an NIH-sponsored expanded access program (EAP). Etherington said Clene is presenting these findings to the agency as part of its regulatory package.

He added that the FDA is focused not just on whether CNM-Au8 reduces neurofilament, but whether “the magnitude of that drop,” which he described as about 10%, is likely to predict clinical benefit.

Company outlines clinical-benefit analyses supporting NDA filing

Etherington said Clene is using multiple lines of evidence to argue that changes in neurofilament track with clinical outcomes. He cited analyses that examine:

• Survival
• Functional outcomes using the ALSFRS-R scale
• Biomarker-to-clinical concordance evaluating whether neurofilament changes align with clinical benefit

He described Clene’s approach as assessing whether neurofilament benefit predicts clinical outcome, whether there is a durable effect on function, whether treatment benefit concentrates in neurofilament responders, and whether survival tracks neurofilament response. “It’s a very simple kind of one equals two equals three equals four,” Etherington said, while acknowledging it involves “a lot of data” that has been sent to the FDA.

Etherington also reiterated that survival remains an important part of the company’s overall evidence base, calling it “the thing that cannot be unseen.” He said the company has observed survival benefit across multiple comparisons, including against placebo datasets, in open-label active patients, in placebo patients who convert to active treatment, and against concurrent controls. However, he emphasized that survival is not the basis for the accelerated-approval approach Clene is pursuing.

Financing update and MS program plans

On funding, Etherington said the company saw significant trading activity after it announced its data and that a new investor participated, allowing Clene to raise money. He also referenced a potential additional cash event tied to an FDA review timeline. “When our PDUFA date is given, if/when our PDUFA date is given, then that will be another execution of nearly $7 million,” he said, adding that the cash provides runway to continue the regulatory process and prepare for the “possibility of approval next year” if the FDA concurs with Clene’s data.

Separately, Etherington addressed CNM-Au8’s potential in multiple sclerosis (MS), saying Clene has had “two dialogues with the FDA” on the indication. He said there is “no chance” of early approval in MS and that the company would need to conduct a Phase 3 clinical study. Etherington said the Phase 3 design would focus on cognition in people already receiving MS drugs that reduce lesions, targeting those with progressive MS. He said Clene is working with advisors and experts on the design and is in dialogue with the FDA’s Division of Neurology 1 regarding execution of the Phase 3 study next year.

About Clene NASDAQ: CLNN

Clene NASDAQ: CLNN, also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.